Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Active not recruiting 5Recruiting 3Completed 2Withdrawn 1

Sponsor Class

OTHER 2FED 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 20Lymphoma, Mantle-Cell 11Lymphoma, Large B-Cell, Diffuse 5Leukemia, B-Cell 4Lymphoma 3Lymphoma, Non-Hodgkin 2Leukemia 2Lymphoproliferative Disorders 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphatic Diseases 1Heart Failure 1

Interventions

Cyclophosphamide 28fludarabine 19Rituximab 17obinutuzumab 12venetoclax 10Lenalidomide 9Bendamustine Hydrochloride 9Prednisone 7zanubrutinib 6Doxorubicin 6Blood Specimen Collection 6pembrolizumab 5ibrutinib 5fludarabine phosphate 5Biopsy 5glofitamab 4Vincristine 4Trimethoprim, Sulfamethoxazole Drug Combination 4Exercise 4loncastuximab tesirine 3gamma-Globulins 3axicabtagene ciloleucel 3acalabrutinib 3Temozolomide 3Surveys and Questionnaires 3Palliative Care 3Mycophenolic Acid 3Methotrexate 3Mesna 3Magnetic Resonance Spectroscopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Lymphoma × acalabrutinib × Clear all
NCT04855695 2026-01-21

Avo In R/R And Previously Untreated MCL

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
72 enrolled
Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

NCT07052695 2025-12-15

Mosunetuzumab for CLL MRD Clearance

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
40 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06520098 2025-10-14

Benefit VA

VA Office of Research and Development

Phase 2 Recruiting
100 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡